The QualityStocks Daily Friday, October 5th, 2018

Today's Top 3 StockMarketWatch

QualityStocks (OPVS) +58.13%

StockMarketWatch (GTXI) +35.46%


The QualityStocks Daily Stock List

Q BioMed, Inc. (QBIO)

Insider Financial, Proactive Investors, SeeThruEquityResearch, Market Screener, Stock News Now, Tip Ranks, Investing News, Simply Wall St, StockPicksNYC, and Barchart reported on Q BioMed, Inc. (QBIO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Q BioMed, Inc. is a commercial stage biomedical acceleration and development company based in New York, New York. The Company’s dedication is to licensing and acquiring biomedical assets across the healthcare spectrum. The Company formerly went by the name ISMO Tech Solutions, Inc. It changed its corporate name to Q BioMed, Inc. in July of 2015. Q BioMed’s shares trade on the OTC Markets’ OTCQB.

Q BioMed’s commitment is to provide these target assets the strategic resources, developmental support, and expansion capital they require to ensure they meet their developmental potential, enabling them to provide products to patients in need. The Company’s mission is to license and acquire unique life sciences assets from academia or small private companies.

Q BioMed is concentrating on clinical stage and innovative products where the technical, regulatory, and commercial risks have been lessened or significant valuation modulations are pending. The Company has numerous assets across a broad array of healthcare related products, companies, and sectors. These assets will undergo development to provide returns via organic growth or out-licensing, sale, or be spun out into new public companies.

Q BioMed has commenced production of Strontium-89 Chloride - a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain. AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be used in combination with, or to reduce the requirement for opiate based drugs, and also in combination with cancer therapeutic drugs.

Q BioMed is also developing a unique molecule delivered in an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the decreasing of IOP (Intraocular Pressure) . Q BioMed, together with its partner, Mannin Research, Inc, is the only company targeting this mechanism of action.

In August, Q BioMed and BioNucleonics, licensor of Strontium 89 Chloride, announced the submission of a supplemental regulatory filing to the Food and Drug Administration (FDA) for the approval of a new manufacturing facility. Upon clearance by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP in accordance with cGMP. Strontium Chloride Sr89 Injection USP is an FDA-approved non-opioid injectable radiopharmaceutical indicated to relieve cancer bone pain in patients with painful skeletal metastases.

In September, Q BioMed announced that it entered into a definitive agreement with Yorkville Advisors Global for $4,000,000. The Company closed on the initial tranche of $2,000,000. It expects to close on the balance pending the filing of a registration statement with the U.S. Securities and Exchange Commission (SEC) for the underlying shares.

Q BioMed will use the funds for the drug launch for Strontium Chloride 89 USP Injection for Bone Cancer Palliation; the Orphan Drug Application and Pre-IND filings for QBM-001 (Autism Spectrum Disorder Drug); for final synthesis data on Uttroside B (Liver Cancer), and molecule selection for Man01 (Glaucoma).

Q BioMed, Inc. (QBIO), closed Friday's trading session at $2.99, up 2.75%, on 53,739 volume with 114 trades. The average volume for the last 3 months is 100,018 and the stock's 52-week low/high is $1.67/$5.90.


Medicine Man Technologies, Inc. (MDCL)

Stockwatch, Insider Financial, Stockopedia, Marketbeat, Stockhouse, Insider Tracking, Simply Wall St, Daily Marijuana Observer, The Street, CFN Media Group, and MarketWatch reported on Medicine Man Technologies, Inc. (MDCL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Medicine Man Technologies, Inc. represents and licenses the cultivation and dispensary Intellectual Property (IP) of Medicine Man - a well-respected Tier III operator in Colorado. Medicine Man Technologies provides cultivation consulting services for cannabis growing technologies and methodologies. The Company is one of the nation’s top cannabis brand development and consulting enterprises. Medicine Man Technologies has its head office in Denver, Colorado.

Medicine Man is concentrating on working with clients to use its experience, technology, and training to help secure licenses in states with newly emerging regulations. Furthermore, the Company is focusing on cultivation practices by way of its deployment of Cultivation MAX and eliminating the liability of single grower dependence.

Medicine Man Technologies works closely with industry-leading extraction partners. These partners provide the necessary licensing service support and formulations to help customers with their planned deployment of a successful processing facility.

Medicine Man’s risk-averse cannabis cultivation technology delivers consistent, high quality, high yield production within a clean-room style environment. The Company’s state-of-the art dispensary model ensures patients and consumers have safe and secure access to a variety of medical and/or recreational cannabis products.

Moreover, Medicine Man Technologies is continuing the expansion of its Brands Warehouse concept. In addition, it engages in retail operations of cannabis products. The Company also provides general business and referral management for other related service providers for its customers. Medicine Man cultivates and sells through its parent company Medicine Man Denver, the largest cultivation/retail facility in Colorado.

Medicine Man Technologies and Solis Tek, Inc. have a cooperative agreement. Solis Tek will become Medicine Man Technologies' recommended supplier of High Intensity Discharge (HID) lighting technologies for its present and prospective consulting and sales relationships. Medicine Man has completed and totally integrated three acquisitions. These are Pono Publications, Success Nutrients, and the Denver Consulting Group.

Recently, Medicine Man Technologies announced it completed the acquisition of the Big Tomato retail supplier business effective September 17, 2018. The Big Tomato retail business has been open since 2001. The anticipation is that it will produce about $2.5M in revenues in 2018. The business carries a broad assortment of grow related products. In addition, it will be acting as another distribution hub for Medicine Man’s Success Nutrients product line.

Mr. Jeremy Stout, Big Tomato’s Managing Partner, stated, “My partners and I are very excited about this new opportunity to align ourselves with Medicine Man Technologies, Inc. We all believe we can provide the Company’s clients with competitive pricing for their nutrient products that will continue to meet their respective specifications through our established relationships in the cannabis industry.”

Medicine Man Technologies, Inc. (MDCL), closed Friday's trading session at $1.58, up 3.10%, on 37,986 volume with 68 trades. The average volume for the last 3 months is 69,092 and the stock's 52-week low/high is $1.03/$3.40.


Cantabio Pharmaceuticals, Inc. (CTBO)

Profitable Trader Authority, HotStockProfits, Profitable Trading, Leeb’s Market Forecast, AwesomeStocks, OTCtipReporter, Investors Alley and PennyStockScholar reported previously on Cantabio Pharmaceuticals, Inc. (CTBO), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Cantabio Pharmaceuticals, Inc. centers on bringing novel, first-in-class drug candidates into clinical trials and beyond. The Company does so through the discovery and development of ground-breaking pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders. These include Alzheimer’s, Parkinson’s, and oxidative stress. At present, Cantabio is engaging in advanced pre-clinical trials of its therapeutic candidates and is focused on developing these towards clinical trials. A preclinical stage biotechnology company, Cantabio Pharmaceuticals is headquartered in Sunnyvale, California.

The Company is concentrating on commercializing novel therapies and the Intellectual Property (IP) produced from its research and development (R&D) activities for Parkinson’s disease (PD), Alzheimer’s disease (AD), and other related neurodegenerative diseases. Cantabio’s strategy combines a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach.

In addition, Cantabio is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins, which display loss of function during disease conditions. The Company has a new preclinical therapeutic program for Alzheimer’s disease that it is pursuing through its drug discovery partnership with NovAliX. The program is targeted at the development of small molecule chaperones that stabilize the Abeta peptide, the aggregation of which is considered to be a vital element in the onset and progression of Alzheimer’s disease.

This week, Cantabio Pharmaceuticals’ Dr. Gergely Toth, the Company’s Chief Executive Officer, presented the latest results from Cantabio's DJ-1 protein targeting small molecule pharmacological chaperone therapeutic program at the Milner Therapeutics Symposium on October 1, 2018. The Symposium is a key networking event for drug discovery professionals and Milner Therapeutics Institute alliance partners that includes companies such as AstraZeneca, GlaxoSmithKline, Shionogi, Pfizer and Johnson and Johnson.

DJ-1 is a novel and crucial target for the treatment of several conditions, as loss of DJ-1 protein function has been linked to the onset of an array of diseases including Parkinson’s disease, Alzheimer’s disease, stroke, amyotrophic lateral sclerosis, chronic obstructive pulmonary disease and type II diabetes. The DJ-1 protein is considered to be one of the chief therapeutic targets for Parkinson’s disease, as it is genetically linked to the onset of familial Parkinson’s.

Cantabio Pharmaceuticals, Inc. (CTBO), closed Friday's trading session at $0.014, down 3.45%, on 192,500 volume with 12 trades. The average volume for the last 3 months is 122,959 and the stock's 52-week low/high is $0.009/$0.129.


TheMaven, Inc. (MVEN)

InvestorsHub and Stockhouse reported on TheMaven, Inc. (MVEN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

TheMaven, Inc. is an expert-driven, group media network. Its advanced platform serves, by invitation-only, an alliance of professional, independent channel partners. TheMaven’s Executive team and operational Board members include digital media pioneers Mr. James Heckman and Mr. Ross Levinsohn, and technology innovators Mr. Bill Sornsin and Mr. Ben Joldersma. A digital media start-up, TheMaven is based in Seattle, Washington.

Maven provides elite content leaders an end-to-end digital platform within a cooperative that shares resources and distribution and maximizes monetization. Maven enables partners to focus on the essential drivers of their businesses - creating, informing, sharing, discovering, leading, and interacting with the communities and constituencies they serve. The Company enables partners to do so through providing broader distribution, more community engagement, and efficient advertising and membership programs.

Maven announced in January of this year that it agreed to acquire HubPages in a union that brings together greater than 40 million monthly unique users in a single premium digital media network, the two companies announced after signing a Letter of Intent (LOI).

HubPages’ network will undergo migration to Maven’s publishing and community platform, relaunched as part of a single premium network, on one platform for advertisers. The expectation is that moving the network to Maven will improve traffic, engagement, and monetization. HubPages will remain a vital “cultivating” network, at

Maven is partnering with to provide Maven’s content creators protection from improper use of their content and ensure fair monetization. is a blockchain-based open universal ledger for digital creative assets. will provide Maven publishers with the ability to timestamp and validate their content and digital assets in an unchangeable system, which will automatically issue digital ownership certificates.

In late March of this year, Maven announced it signed a Letter of Intent (LOI) to acquire Say Media as part of a three-way fusion, along with HubPages, which will bring together former competitors to create a dominant platform for professional, independent publishers. Maven, Say Media, and HubPages will continue to trade under the MVEN ticker symbol.

Furthermore, Maven is adding team-sports “franchises” to its extensive coalition of elite independent publishers (mavens). It is doing so through re-launching a business model its Founders invented more than two decades ago at

Maven is partnering with The Sports Xchange (TSX) to implement a nationwide, professional network of sports journalists. These journalists will provide authentic, on-the-ground content, analysis and community engagement for fans of every professional and major college team in North America.

TheMaven, Inc. (MVEN), closed Friday's trading session at $0.6402, up 4.95%, on 12,362 volume with 11 trades. The average volume for the last 3 months is 16,569 and the stock's 52-week low/high is $0.43/$2.573.


NanoFlex Power Corp. (OPVS)

Dividend Investor, Zacks, Wallet Investor, Stockhouse, MarketWatch, MicroCapResearch, InvestorsHub, Super Stock Screener, and Morningstar reported earlier on NanoFlex Power Corp. (OPVS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

NanoFlex Power Corp. engages in the research, development, and commercialization of advanced configuration solar technologies. These technologies enable innovative thin-film solar cell implementations. The Company believes these will be industry-leading efficiencies, light weight, flexible, and low total system cost. Listed on the OTC Markets Group’s OTCQB, NanoFlex Power has its corporate office in Scottsdale, Arizona.

The Company’s sponsored research agreements provide it with the exclusive worldwide license and right to sublicense any and all Intellectual Property (IP) resulting from the related research and development (R&D) efforts at different universities. NanoFlex Power entered into a license agreement with SolAero Technologies Corp. For the last two-plus years, the Company and SolAero have partnered to validate NanoFlex's patented, non-destructive epitaxial lift-off (ND-ELO) process and related technologies in SolAero's ultra-high efficiency solar cells.

SolAero is a global leader in high performance photovoltaics for space and terrestrial applications. SolAero is a leading manufacturer of high efficiency solar cells.

NanoFlex Power is part of a consortium that was awarded a $6.5 million contract from the Army Research Laboratory's Army Research Office. This consortium comprises NanoFlex Power, SolAero Technologies, the University of Michigan (UM), and the University of Wisconsin (UW). The contract is to develop high power, flexible, and lightweight solar modules for portable power applications with more than double the power of existing flexible solar modules within the same footprint at a competitive procurement cost on a dollars per Watt basis.

Research programs have produced two solar thin film technology platforms. One is Gallium Arsenide (GaAs) thin film technology for high power applications. The other is organic photovoltaic (OPV) technology for applications requiring high quality aesthetics.

NanoFlex Power has the exclusive worldwide rights to license, sublicense, and bring its own products to market using the aforementioned ND-ELO technology. ND-ELO technology has the potential to reduce compound semiconductor production costs by greater than 40 percent through enabling reuse of the expensive wafer substrate.

NanoFlex Power Corp. (OPVS), closed Friday's trading session at $0.1265, up 58.13%, on 16,000 volume with 5 trades. The average volume for the last 3 months is 28,889 and the stock's 52-week low/high is $0.0019/$0.5692.


Pharma-Bio Serv, Inc. (PBSV)

Zacks, Stockopedia, Dividend Investor, Business Wire, Stockhouse, MarketWatch, InvestorsHub, Capital Cube, Wallet Investor, Morningstar, YCharts, GuruFocus, Market Screener, Barchart, Marketbeat and Marketwired reported on Pharma-Bio Serv, Inc. (PBSV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Pharma-Bio Serv, Inc. is a compliance, project management, and technology transfer support consulting firm. The Company’s principal business is Food and Drug Administration (FDA) and other international regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services. This includes microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, and Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico.

Pharma-Bio Serv has its head office in Dorado, Puerto Rico. Additionally, the Company has operations in the United States Ireland, and Spain. Pharma-Bio Serv lists on the OTCQB.

Pharma-Bio Serv supports its clients through the product lifecycle. This includes research and development (R&D) Studies; NDA Documentation and Filings; PAI Readiness; Audit & Inspection Preparation, Management and Response, and Post Approval. In addition, this includes Quality Systems; Technology Transfer; Validation, as well as Manufacturing Controls & Process Support.

Furthermore, the Company’s services include "Pharma Serv Academy." This division provides technical and regulatory standards seminars/training conducted by industry experts.

Pharma-Bio Serv’s divisions include Scienza Labs, the PharmaServ Academy, and Metrologix. Scienza Labs provides microbiological and analytical testing, field support, method development, and validation. Metrologix provides laboratory and on-site calibration services, calibration program management, risk management, compliance remediation, and instrument rental.

In September, Pharma-Bio Serv announced it completed the sale of substantially all of the assets of its laboratory business to Romark Global Pharma, LLC for $5 million ($2.0 million in cash, and $3.0 million in the form of a promissory note payable over two years).

Mr. Victor Sanchez, Pharma-Bio Serv’s Chief Executive Officer, said, "With the completion of the sale, we move forward with our strategy to concentrate our focus and efforts on our core consulting business, and streamline our operating segments."

Recently, Pharma-Bio Serv announced Net Revenues for the three and nine months ended July 31, 2018 were $5.2 and $13.8 million, respectively. This represents an increase of roughly $1.2 and $1.9 million, or 31.0 percent and 15.8 percent, respectively, versus the same periods the year prior.

Pharma-Bio Serv, Inc. (PBSV), closed Friday's trading session at $1.00, down 7.41%, on 17,420 volume with 18 trades. The average volume for the last 3 months is 9,538 and the stock's 52-week low/high is $0.399/$1.08.


MGX Minerals, Inc. (MGXMF)

MarketWatch, 4-Traders, InvestorsHub, Stockhouse, OTC Markets, Morningstar, Capital Equity Review, The Street, Stockwatch, The StreetWise Reports, and Barchart reported on MGX Minerals, Inc. (MGXMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MGX Minerals, Inc. is a diversified resource company headquartered in Vancouver, British Columbia. It focuses on the development of large-scale industrial mineral portfolios in specific commodities and jurisdictions that will fuel the new energy economy. MGX Minerals controls significant interest in lithium, magnesium and silicon assets across North America. The Company lists on the OTC Markets Group’s OTCQB.

MGX Minerals’ strategy is to identify commodities and jurisdictions where large-scale development opportunities exist. Moreover, the Company’s strategy is to build its asset portfolio through aggressive acquisition to quickly build and enhance long-term portfolio value. Furthermore, its strategy is to engage industry experts to decrease execution risk and quickly increase time to market.

The Company has regional control in the majority of industrial mineral projects in the jurisdictions it operates. Concerning near-term potential, MGX concentrates on assets that offer streamlined development timelines and low initial capital expenditures.

MGX has developed a proprietary, low-energy design process (Rapid Recovery Process) that is patent-pending. The design of it is purposely for highly-mineralized brine associated with oilfields. The process quickly concentrates lithium and other minerals in brine.

Regarding independent confirmation of the Rapid Recovery Process, testing was carried out by a third-party laboratory (Saskatchewan Research Council (SRC)). SRC successfully recovered 83.7 percent of lithium from a representative sample of brine. Lithium was concentrated to 461 ppm from the representative sample containing 71 ppm.

MGX Minerals has completed pilot plant testing in South America on brine samples originating from numerous salars in Chile. The Company has entered into a joint brine testing agreement with several South American mining companies. The parties are now working to identify potential joint-venture (JV) locations that will utilize MGX Minerals’ lithium extraction technology.

MGX Minerals announced this past July that it entered into a Property Option Agreement with Belmont Resources. This Agreement is to acquire an initial 25 percent interest in the Kibby Basin, Nevada lithium brine property, around 50 km North of Clayton Valley, Nevada.

This week, MGX Minerals reported that engineering subsidiary PurLucid Treatment Solutions is shipping the first petrolithium and advanced wastewater treatment system on Monday, October 8, 2018. The commercial-scale 750 barrel per day (bpd) system will be delivered to a centralized treatment and processing facility north of Edmonton and close to the Alberta oilsands. By installing the system at a centralized facility, PurLucid will be able to take delivery of wastewater brine from manifold clients.

Today, MGX Minerals announced it has been nominated in two categories as a finalist for the 2018 S&P Global Platts Global Energy Awards. The Company has been selected as a finalist for the Emerging Technology and Rising Star awards. Global Energy Awards Finalists were selected from a pool of over 200 nominations and across 25 countries. Winners of the 2018 Global Energy Awards will be announced at a black-tie celebration on December 6, 2018 at the Cipriani - Wall Street in New York, New York.

MGX Minerals, Inc. (MGXMF), closed Friday's trading session at $0.44188, up 6.94%, on 94,370 volume with 70 trades. The average volume for the last 3 months is 426,533 and the stock's 52-week low/high is $0.384/$1.58.


Breaking Data Corp. (BKDCF)

Barchart, Small Cap Exclusive, OTC Markets, InvestorsHub, Morningstar, CapitalEquityReview, SavvyTraderResource, Stockhouse, FinanceSpotlight, Capital Cube, Marketwired, The Street, MarketWatch, Seeking Alpha, 4-Traders, and Penny Stock Tweets reported on Breaking Data Corp. (BKDCF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Breaking Data Corp. is a technology provider of a range of Artificial Intelligence (AI) services. These include semantic search, machine learning, and natural language processing (NLP). The Company formerly went by the name Sprylogics International Corp. It changed its corporate name to Breaking Data Corp. in September 2015. Listed on the OTCQX, Breaking Data is based in Concord, Ontario.

Breaking Data’s technology platform has numerous practical applications in many business and consumer verticals, which are immersed in massive media and data rich settings. Its showcase app is BreakingSports. The Company’s BreakingSports utilizes semantic machine learning and NLP to track social media in a completely automated, real-time manner for major sports information and events. BreakingSports distributes summarized information via real-time push notifications to consumers.

Breaking Date has acquired GIVEMESPORT. It is now the Company’s wholly-owned subsidiary. GIVEMESPORT is a leading next generation sports media business. Breaking Data has launched a unique Artificial Intelligence (AI)-powered App focused on personalization, speed and user experience. The GIVEMESPORT Android App is available on the Google Play Store.

Powered by Breaking Data’s AI, Natural Language Processing and Machine Learning technology, the GIVEMESPORT’s App provides premier access to sports news, scores, videos, stats, and live match updates and news from trusted sources in sports.

Last month, Breaking Data announced it sold its Toronto-based technology team to Highground Technologies Corporation for an undisclosed sum. With this deal with Highground, Breaking Data will retain an agreement, which will allow the Company to use the Artificial Intelligence (AI) previously built and to continue to develop machine-learning based systems for GIVEMESPORT and GIVEMEBET.

GIVEMEBET is a new online sports betting brand. It will complement GIVEMESPORT’s foremost position in digital sports publishing. Breaking Data will retain a 10 per cent stake in VRFY, which is a subsidiary of Highground Technologies. VRFY is a 21st century media company. VRFY employs AI to help consumers detect, collect, as well as validate real time news events.

Breaking Data Corp. (BKDCF), closed Friday's trading session at $0.43414, even for the day. The average volume for the last 3 months is 1,825 and the stock's 52-week low/high is $0.36/$2.43.


Relmada Therapeutics, Inc. (RLMD)

Dividend Opportunities, StreetAuthority Financial, SmallCap Network, Trade of the Week, Investopedia, ProfitableTrading, Wallstreetbuzz, Investors Alley, The Observer, PCG Advisory, Streetwise Reports, Penny Stock Bets, and WallstreetsHotteststocks reported on Relmada Therapeutics, Inc. (RLMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Relmada Therapeutics, Inc. is a clinical-stage, specialty pharmaceutical company. It centers on developing novel versions of proven drug products in combination with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diverse portfolio of lead products at different stages of development. It is developing novel therapies for the treatment of central nervous system (CNS) diseases. Relmada Therapeutics is headquartered in New York, New York.

The Company’s lead products are d-Methadone (REL-1017), its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine -MepiGel (REL-1021), its orphan drug designated topical formulation of the local anaesthetic mepivacaine; oral buprenorphine - BuTab (REL-1028), its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol.

BuTab (REL-1028) is its investigational, oral formulation of buprenorphine - an opioid that is extensively used to treat addiction and chronic pain. The design of BuTab is to be delivered orally and reach safe and effective blood levels of buprenorphine through the gastrointestinal route of administration due to its modified release profile.

Relmada Therapeutics announced in April 2017 that the Food and Drug Administration (FDA) granted Fast Track designation for d-Methadone (REL-1017 dextromethadone), Relmada’s novel N-methyl-D-aspartate (NMDA) receptor antagonist in development for the adjunctive treatment of major depressive disorder.

Relmada Therapeutics announced earlier that the European Patent Office issued a notice of allowance for patent application number 13773543.7 for "D-methadone for the treatment of psychiatric symptoms." This patent provides wide-ranging coverage in Europe for d-Methadone (dextromethadone, REL-1017). Moreover, the Company earlier announced that it acquired the international rights to develop and market dextromethadone (REL-1017).

Recently, Relmada Therapeutics announced that Dr. Ottavio Vitolo joined the Company as Senior Vice President, Head of Research and Development and Chief Medical Officer. Dr. Vitolo earlier served as Executive Clinical Advisor of Relmada since June 2017.

In this new role, Dr. Vitolo will manage the clinical development program for Relmada Therapeutics’ lead product candidate, dextromethadone (REL-1017), and will lead the expansion of the portfolio to other CNS indications.

Relmada Therapeutics, Inc. (RLMD), closed Friday's trading session at $1.03, up 0.98%, on 578 volume with 6 trades. The average volume for the last 3 months is 7,115 and the stock's 52-week low/high is $0.61/$1.94.


SANUWAVE Health, Inc. (SNWV)

InsidersLab, KillerPennyStocks, Marketbeat, RedChip, TopPennyStockMover, SmallCapVoice, PennyStocks24, OTC Stock Review, Penny Stock Rumble, Streetwise Reports, Greenbackers, OTCJournal, FeedBlitz, AllPennyStocks, OTC Stock Review, Explicit Penny Picks, Free Investment Report, Free Penny Alerts, Gladiator Stocks, The Green Baron, and Ox of Wallstreet reported on SANUWAVE Health, Inc. (SNWV), and we also report on the Company, here at the QualityStocks Daily Newsletter.

SANUWAVE Health, Inc. is a shock wave technology business. The Company’s initial emphasis is on the development and commercialization of patented non-invasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE Health researches, designs, and manufactures, markets and services its products globally. OTCQB-listed, SANUWAVE Health is headquartered in Suwanee, Georgia.

SANUWAVE’S lead product candidate for the worldwide wound care market, dermaPACE®, is CE marked across Europe. It has Canada, Australia, and New Zealand device license approval for the treatment of skin and subcutaneous soft tissue.

The Company applies its patented Pulsed Acoustic Cellular Expression (PACE®) technology in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions. Its portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses. This produces new vascularization and microcirculatory improvement. This helps in restoring the body's normal healing processes and leads to regeneration of tissue.

SANUWAVE’S belief is that it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) by way of its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the use of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific.

There are license/partnership opportunities for the Company’s shock wave technology for non-medical uses. This includes energy, water, food, and industrial markets.

SANUWAVE Health announced this past February that a partnership agreement was reached with Premier Shockwave Wound Care, Inc. and Premier Shockwave, Inc. (collectively Premier).  This agreement will cover the Veteran’s Administration (VA), Indian Health Service (IHS) and Tribally operated healthcare services, and US Military facilities/bases (MTFs).

Premier will purchase an undisclosed number of dermaPACE units to service these end markets. SANUWAVE Health will receive revenue from the sale of the equipment and a per procedure fee from Premier. This contract includes a minimum purchase of 100 units over three years.

Last month, SANUWAVE Health reported financial results for the three months ended March 31, 2018. Revenue for Q1 2018 was $344,272, an increase of 130 percent from Q1 2017. The Company shipped its first US dermaPACE® devices in February 2018.

Moreover, SANUWAVE Health added Dr. Perry Mayer, Medical Director and Principal at The Mayer Institute “TMI” in Hamilton, Ontario, Canada to the Science Advisory Board.

In the U.S., dermaPACE® has received U.S. Food and Drug Administration (FDA) de novo clearance for the treatment of Diabetic Foot Ulcers (DFU’s). SANUWAVE Health announced in January 2018 that the FDA issued its decision on the de novo submission for the dermaPACE® System.  Its decision (dated December 28, 2017) permits the marketing of the dermaPACE System as a Class II medical device used for the treatment of Diabetic Foot Ulcers (DFU) in the United States.

With the FDA clearance, SANUWAVE has started to develop and implement a platform for rolling out the dermaPACE® System for treating DFU’s in the United States.  

SANUWAVE Health, Inc. (SNWV), closed Friday's trading session at $0.17, up 3.03%, on 54,563 volume with 16 trades. The average volume for the last 3 months is 165,233 and the stock's 52-week low/high is $0.10/$0.6419.


Green Spirit Industries, Inc. (GSRX)

RedChip, Barchart, Stockhouse, InvestorsHub, 4-Traders, Simply Wall St, OTC Markets, YCharts, Wallet Investor, and Business Insider reported on Green Spirit Industries, Inc. (GSRX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Green Spirit Industries, Inc., via its subsidiaries, acquires, develops, and operates retail cannabis dispensaries. Additionally, the Company is in the process of expanding its business to include the cultivation, extraction, manufacture and delivery of cannabis and cannabinoid products. Green Spirit Industries has its corporate office in Dorado, Puerto Rico.

On June 18, 2018, Green Spirit Industries announced that its stock started trading on the OTCQB Market on June 13, 2018, after successfully uplisting from the OTC Pink Market. The OTCQB is a venture market. The design of the OTCQB is for early-stage and developing U.S. and international companies.

Green Spirit Industries holds a 55 percent majority stake in a newly established joint venture (JV) with Sunset Connect SF, Inc. It created Sunset Connect Oakland, LLC, which is in the process of establishing cannabis cultivation/growing operations;

Green Spirit also holds a 55 percent majority stake in a newly established JV with Sunset Connect SF, in which it created Green Spirit Essentials, LLC, which is in the process of establishing a cannabinoid extractions and processing business.

Furthermore, Green Spirit holds a 51 percent majority stake in a newly established JV with Solunas Aqua Corp., called Spirulinex, LLC, which has developed an extensive slate of cannabinoid ingestibles, and which has numerous patents pending.

As of June 11, 2018, Green Spirit Industries operates four cannabis dispensaries under the Green Spirit RX and The Green Room names. The Company has acquired and operates the four cannabis dispensaries in California and Puerto Rico. It has acquired four more pre-qualified locations in Puerto Rico. All of these are under construction with expected openings later in 2018.

The new Green Spirit RX medicinal cannabis dispensaries in Puerto Rico are located in Carolina, just east of San Juan, and in the Hato Rey district of San Juan.  Green Spirit Industries began operations of its first Green Spirit RX medicinal cannabis dispensary in Dorado, Puerto Rico this past April.

In Puerto Rico, to date, Green Spirit Industries has acquired a total of seven pre-qualified medicinal cannabis dispensaries, with locations in Dorado, Carolina, Fajardo, San Juan (2 locations), Bayamón and Isla Verde. The Company has started operations at its dispensaries in Dorado, Carolina, and San Juan (Hato Rey).

Furthermore, Green Spirit has almost completed construction on its two dispensaries in Fajardo and San Juan (Andalucia); and commenced construction on its two dispensaries in Isla Verde and Bayamón.

During Q1 2018, Green Spirit Industries expanded its operations into the California market. The Company acquired an established retail storefront cannabis dispensary named “The Green Room” located in Point Arena, Mendocino County.

Green Spirit Industries, Inc. (GSRX), closed Friday's trading session at $1.48, up 2.07%, on 3,429 volume with 12 trades. The average volume for the last 3 months is 13,852 and the stock's 52-week low/high is $1.38/$11.45.


Wrap Technologies, Inc. (WRTC)

Stockwatch, Jet Life Penny Stocks, Stockflare, Wall Street Pennies, VentureLine, High Rising Stocks, Penny Stock Hub, Stockhouse, Simply Wall St, Investors Hangout, Trading View, Investing News Alerts, and Street Insider reported on Wrap Technologies, Inc. (WRTC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Wrap Technologies, Inc. is an innovator of modern policing solutions. It premiered its hand-held BolaWrap™ 100 remote restraint solution at the International Association of Police Chiefs (IACP) October 2017 international conference. The Company’s technology assists law enforcement and military in safely and effectively controlling encounters. Wrap Technologies has its corporate headquarters in Las Vegas, Nevada.

Award winning inventor Elwood Norris developed BolaWrap™ 100. The BolaWrap™ 100 is a hand-held remote restraint device. It discharges an eight-foot bola style Kevlar tether to entangle an individual at a range of 10-25 feet.

The BolaWrap 100 is a restraint tool for Police and Military. It can be used early in an encounter between officer and suspect so as to prevent unnecessary escalation and violence.

BolaWrap 100 is light and operable by an officer using support hand. Remote restraint helps in controlling subjects. The design of it is to remotely restrain without uncontrolled falls.

BolaWrap 100 features rapid cartridge refresh to support multiple wraps. The design of the product is to safely and effectively control encounters by remotely wrapping a subject's legs, limiting the need for potentially injurious less lethal or lethal force.

Yesterday, Wrap Technologies announced that field testing of the new BolaWrap 100 remote restraint device is scheduled to begin with the Park City (Utah) Police Department. The Company has provided Park City with equipment to deploy to identify the best use cases for BolaWrap remote restraint and measure effectiveness as an early engagement tool.

Wrap Technologies has an increasing number of product partnerships with high profile agencies designed to ensure the BolaWrap 100 meets customer requirements to restrain noncompliant individuals.

Mr. David Norris, Wrap Technologies’ President, said, "We are excited that the Park City Police Department is joining other select agencies to evaluate BolaWrap 100. We are seeing a rapid transition from evaluation to field test deployment. Park City and other agencies are also engaging local media as part of their commitment to less lethal policing especially in mental health settings."

Wrap Technologies, Inc. (WRTC), closed Friday's trading session at $4.75, up 2.15%, on 11,529 volume with 28 trades. The average volume for the last 3 months is 14,486 and the stock's 52-week low/high is $2.09/$9.00.


Freedom Holding Corp. (FRHC)

Stockflare, OTC Markets, Marketbeat, Stockopedia, Stockwatch, Investors Hangout, Barchart, Wallet Investor, Simply Wall St, Stockhouse, Last10K, 4-Traders, InvestorsHub, MarketWatch, Insider Monkey, and The Stock Market Watch reported on Freedom Holding Corp. (FRHC), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Freedom Holding Corp. conducts retail financial brokerage, investment counseling, securities trading, investment banking and underwriting services via its subsidiaries under the name of Freedom Finance in the Commonwealth of Independent States (CIS). A financial services holding company, Freedom Holding has its corporate office in Almaty, Kazakhstan. The Company has executive office locations in the United States and Russia.

Freedom Holding employs greater than 400 experienced professionals throughout branch offices in Kazakhstan, Russia, Kyrgyzstan, Ukraine and Cyprus.

This past April, Freedom Holding announced the opening of its first branch office of Freedom Finance in Tashkent, Uzbekistan. This office will be situated in the city's International Business Center. The office will initially employ 12 investment consultants.

Last month, Freedom Holding announced that its subsidiary Freedom Finance JSC successfully completed the acquisition of Asyl-Invest JSC. The equity capital of Freedom Finance after the transaction exceeds KZT 17.5 billion.

The acquisition joins the two largest retail brokerage firms in Kazakhstan serving over 50,000 client accounts. Freedom Finance JSC is the largest retail brokerage firm in the Republic of Kazakhstan.

This acquisition provides thousands of new investors with access to Freedom Finance's TRADERNET trading platform. The acquisition also provides investors with access to fourteen branch offices across Kazakhstan and greater than 223 employees working as customer consultants, securities analysts and traders in Kazakhstan.

Earlier this month, Freedom Holding announced that its subsidiary LLC IC Freedom Finance (Moscow, Russia based) completed the acquisition of Nettrader Brokerage Company. LLC IC Freedom Finance is currently, in terms of the number of its registered clients, the 8th largest retail securities broker in Russia. This is according to data published by the Moscow Exchange.

This acquisition adds roughly 16,000 clients across Russia to the LLC IC Freedom Finance client base. Moreover, LLC IC Freedom Finance expands its investment technology assets with the acquisition of Nettrader Brokerage Company.

Freedom Holding Corp. (FRHC), closed Friday's trading session at $8.69, up 0.12%, on 10,285 volume with 16 trades. The average volume for the last 3 months is 13,045 and the stock's 52-week low/high is $1.85/$8.68.


BioElectronics Corporation (BIEL)

Barchart, StreetInsider, and InvestorsHub reported on BioElectronics Corporation (BIEL), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

BioElectronics Corporation is a leader in non-invasive electroceuticals. The Company is the maker of an industry leading family of disposable, drug-free, pain therapy devices. Its innovative medical devices safely and effectively treat chronic and acute pain through a unique mechanism of non-invasive sub-sensory neuromodulation. BioElectronics has its head office in Frederick, Maryland.

BioElectronics’ products include ActiPatch and RecoveryRx®. ActiPatch® provides advanced long-lasting chronic pain relief utilizing Electromagnetic Pulse Therapy. It is a new and clinically proven drug free technology in the fight against chronic pain.

RecoveryRx® uses pulsed electromagnetic therapy to reduce pain and inflammation resulting in accelerated patient recovery and improved comfort. For medical professionals, the RecoveryRx® medical device provides a safe and cost-effective pain management therapy.

In addition, the Company’s products include Smart Insole™, Allay® Menstrual Pain Relief, and HealFast® Veterinary Pain Relief. The Smart Insole™ consists of Electro-Pulse micro medical devices. These are embedded in comfortable heel gel inserts.

HealFast® Therapy is a drug-free therapy for horses, cats and dogs. It lessens swelling and pain while it hastens healing of muscle and tendon injuries, sores, and incisions. Allay® is an award-winning drug-free micro medical device. It employs Electromagnetic Pulse Therapy to reduce menstrual pain and discomfort.

BioElectronics announced this past March the commencement of a clinical study investigating the efficacy of its RecoveryRx® device for postoperative pain management and recovery following total knee arthroplasty surgery. The clinical study will involve 40 subjects who are already scheduled for a knee replacement.

Each subject will be randomly assigned to receive an active device or placebo device. The expectation is that the study will be completed this coming December.

At the end of May, BioElectronics announced that B. Braun Ltd, of Sheffield, United Kingdom (UK) recently completed development of its same day surgical TOTAL Pathway program for joint replacements that includes BioElectronics medical devices. The program is being launched by B. Braun’s UK Group to improve care and lessen the UK healthcare cost of its 160,000 annual hip and knee replacement procedures.

The “fast-track" same day hip and knee replacements are being supported by hospital physiotherapy teams visiting patients at their homes and communicating utilizing a specialized wireless tablet. Each patient will be given an ActiPatch medical device and a prescription for six additional ActiPatch devices. A comparable program is being put into operation for spinal surgeries.

BioElectronics Corporation (BIEL), closed Friday's trading session at $0.0025, up 4.17%, on 12,297,071 volume with 72 trades. The average volume for the last 3 months is 29,696,535 and the stock's 52-week low/high is $0.0005/$0.005.


The QualityStocks Company Corner

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Medical Cannabis Payment Solutions’ (OTC: REFG) ‘Green’ is a first tier digital payment system that creates a safe and non-cash environment for cannabis dispensaries and retailers, solving the key issues that have been addressed at industry conferences – security and fraud prevention (

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.031, up 9.54%, on 692,610 volume with 39 trades. The average volume for the last 3 months is 373,423 and the stock's 52-week low/high is $0.0161/$0.092.

Recent News


Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH).

Consorteum Holdings (OTC: CSRH) is a mobile platform company focused on delivering compliant, complex mobile-based transactions through partnerships, license agreements and joint venture revenue share arrangements. To view the full article, visit:

Consorteum Holdings, Inc. (CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company’s commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ (“UMI”) solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company’s UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum’s wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company’s UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI’s technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum’s primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum’s management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum’s management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors.

Consorteum Holdings, Inc. (CSRH), closed the day's trading session at $0.0016, up 6.67%, on 7,952,730 volume with 38 trades. The average volume for the last 3 months is 1,453,807 and the stock's 52-week low/high is $0.0006/$0.0085.

Recent News


Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (OTC: STLHF).

Lithium-focused exploration company Standard Lithium (TSX.V: SLL) (FRA: S5L) (OTC: STLHF) is working on the development of breakthrough technology to exploit untapped lithium resources. To view the full article, visit:

Standard Lithium Ltd. (OTC: STLHF) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.


Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (OTC: STLHF), closed the day's trading session at $1.23, up 6.96%, on 25,850 volume with 42 trades. The average volume for the last 3 months is 44,978 and the stock's 52-week low/high is $0.605/$2.23.

Recent News


Marifil Mines Ltd. (TSX.V: MFM) (OTC: MFMLF)

The QualityStocks Daily Newsletter would like to spotlight Marifil Mines Ltd. (MFMLF).

Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF), a Canadian junior exploration company dedicated to acquiring resource-rich properties in Argentina, continues to focus its efforts on gold exploration activities at its San Roque property in the South American country, after positive results of the latest diamond core drilling program expanded areas of known mineralization. Also today, NetworkNewsWire released a report on the company detailing how MFMLF recently reported preliminary results for its diamond core drilling program at the Argentine San Roque property, which indicated significant mineralization at the four holes that were tested. To view the full article, visit:

Marifil Mines Ltd. (TSX.V: MFM) (OTC: MFMLF), headquartered in Vancouver, Canada, is engaged in the exploration, evaluation and acquisition of mineral rich resource properties in Argentina. A rising global demand for cobalt and lithium is generating interest in Marifil Mines and its resources located within South America’s famed “Lithium Triangle,” which include 15,267 hectares spanning its recently acquired Ratones and Fraile claims, as well as two lithium properties covering the southern portions of the Carachi Pampa salar in the Argentine province of Catamarca.

The company’s property also includes the Las Aguilas nickel-copper-cobalt deposit property, with more than four contiguous claims in the San Luis province of Argentina. The Las Aguilas property, which is 100% owned by Marifil, is noted as one of the largest cobalt properties in Argentina. Other noteworthy properties in the company’s portfolio include the Toruel copper-silver property, with more than two contiguous claims, and additional potash properties in Punta Colorada, Pedernal and El Carmen.

Marifil’s sizable portfolio of cobalt and lithium claims in what is recognized as the world’s most prolific mining jurisdiction for these resources strategically positions the company to benefit as global initiatives push demand for lithium-ion batteries toward a frenzy. Zion Market Research, a leading research and consulting firm, has forecast that the lithium-ion battery market could hit $67 billion by 2022, realizing a CAGR of more than 13.7% from 2017-2022. Both lithium and cobalt are major components of these energy storage solutions, with industry data indicating that the battery industry currently consumes roughly 42 percent of global cobalt production.

The company is reviving a lithium exploration program that was active in Argentina a decade ago, building on an unexplored mine it owns there. Marifil will utilize a large proprietary geologic and geochemical data base it developed during its 2009 lithium exploration program in the Salta and Catamarca province sites to resume lithium exploration in the region.

Applications for a second mine and negotiations to purchase a third property are underway, which would establish a significant property portfolio of ‘salar’ brine evaporation lakes. Hydrothermal solutions emanating from regional faults in area volcanoes often enrich the brine with lithium, boron, potassium and magnesium.

In addition to nearly 152,000 acres of lithium-staked properties, Marifil owns 887 acres of land for cobalt exploration and 91,565 acres of gold mining rights in an advanced exploration stage in San Roque that company engineers indicate has high gold discovery potential with “excellent infrastructure and mining friendly politics.”

To date, more than $7.5 million has been invested assessing Marifil’s flagship San Roque gold property, including nearly 16,000 meters of diamond core drilling. The property is jointly owned by Marifil and Novagold Resources, with Marifil holding a 51% stake and serving as the current project operator. The company recently commenced a drilling campaign to further evaluate several deposits of significant gold-silver-indium-lead-zinc mineralization on a 4-kilometer-long zone.

Marifil has closed a private placement funding for $2 million that will inject additional life into the company. Proceeds from the funding will benefit acquisition plans, the ongoing drilling program at Marifil’s gold claim and other output from its general working capital accounts.

Robert Abenante, a chartered professional account, serves as president and chief executive officer of the company. He has extensive experience in the public markets and has served as an officer and director of several public and private companies across various industries, with particular success in the mining sector.

Marifil Mines Ltd. (MFMLF), closed the day's trading session at $0.10, up 2.15%, on 11,380 volume with 4 trades. The average volume for the last 3 months is 22,664 and the stock's 52-week low/high is $0.009/$0.165.

Recent News


Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

CannabisNewsAudio announces the Audio Press Release (APR) titled “Growing Cannabis Sector Sees Surge in Acquisitions,” featuring Sugarmade, Inc. (OTC: SGMD). To hear the CannabisNewsAudio version, visit: To read the full editorial, visit:

Sugarmade, Inc. (SGMD) one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include:;; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.


CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.124, up 3.51%, on 1,216,979 volume with 181 trades. The average volume for the last 3 months is 1,850,621 and the stock's 52-week low/high is $0.028/$0.43.

Recent News


Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures (OTC: NUGS) is employing a proprietary branding and partnership model in an effort to adapt to the changing needs of the market as the cannabis industry evolves. To view the full article, visit:

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $3.25, off by 2.99%, on 41,642 volume with 150 trades. The average volume for the last 3 months is 101,230 and the stock's 52-week low/high is $0.0309/$7.13.

Recent News


TMSR Holding Company (NASDAQ: TMSR)

The QualityStocks Daily Newsletter would like to spotlight TMSR Holding Company (TMSR).

TMSR Holding Company (NASDAQ: TMSR), together with its subsidiaries, offers a clean alternative to traditional waste disposal to companies producing industrial solid waste in China. To view the full article, visit:

TMSR Holding Company (NASDAQ: TMSR), together with its subsidiaries, is a recognized leader in the research, development, production and sale of solid waste recycling systems and zero emissions process systems, for the industrial and mining sectors in the People’s Republic of China. The company operates through its wholly owned business divisions: Shengrong Environmental and Wuhan HOST Coating Materials.

TMSR’s Shengrong subsidiary designs, builds, sells and services customized solid waste recycling systems and equipment for some of the largest industries in China. The company provides customers full-service, tailor-made systems from conceptual design to planning, production, modernization, optimization, assembly, start-up, conversions, disassembly, maintenance and servicing of components to complete zero emissions solid waste recycling and process systems.

Utilizing what management believed to be the world’s most advanced technologies of physical magnetic industrial solid waste recovery, Shengrong can process a variety of industrial solid waste materials and is able to extract valuable metal byproducts from the waste without generating any chemical pollution. Shengrong’s patented equipment can process aluminum slag, copper mine tailings, iron mine tailings, red mud manganese tailings, and molybdenum tailings among many others. Unlike traditional chemical-based recovery methods, the company extracts resalable metals from the waste without generating any pollution. The residues are processed to manufacture high-quality construction materials, turning polluted solid waste into valuable industrial materials with zero discharge.

Industrial solid waste recycling and heavy metal removal are significant worldwide technical, financial and environmental issues. Through Shengrong, TMSR is addressing this profound unmet market need by delivering end users a clean alternative to traditional waste disposal. The company intends to leverage these serious unmet needs, expand its patented industrial waste recycling systems to broad international markets, and provide global industrial and mining businesses cost-effective, patented green technology platforms that create new-found revenue streams for end users.

Through Shengrong, TMSR owns two U.S. patents and five patents granted by the Peoples Republic of China, including four invention patents and two utility model patents. The company’s research and development efforts have achieved technological advancements that allow end users to eliminate pollutant discharge as well as generate new revenue streams by selling valuable byproducts extracted from industrial waste.

TMSR subsidiary, Wuhan HOST Coating Materials, is the largest manufacturer of inorganic Zinc-rich resin and one-component epoxy Zinc-rich resin in China. Established in 2010, Wuhan HOST is a leader in the research and development, production and sale of Zinc-rich coating materials throughout the PRC and has a broad customer base that includes some of the foremost enterprises in major industries such as electricity, metallurgy, machinery, chemicals, bridge and shipping. TMSR completed the acquisition of 100% equity interest in Wuhan HOST Coating Materials on May 1, 2018.

Notably, TMSR first went public as JM Global Holding Company, a Special Purpose Acquisition Company (SPAC) formed to effect a merger, asset acquisition or other business combination that had exceptional growth potential. After reviewing over 50 potential targets and completing due diligence and third party analysis, JM Global identified China Sunlong Environmental Technology Inc. and its wholly owned subsidiaries as the acquisition target. Upon closing the business combination, the company was re-named TMSR Holding Company Ltd.

Demand for TMSR’s products is expected to grow significantly due to Chinese policies that encourage mining and manufacturing companies to adopt “green” technology. Approximately 3 billion tons of industrial solid waste were generated annually in China between 2011 through 2015.  Currently, 95% of industrial solid waste in China is stored in special facilities and sites; however, the cost of storage, disposal and incineration of industrial solid wastes is high. TMSR is focused on exploiting this unmet need, providing end users in the solid waste recycling markets a clean alternative to traditional waste disposal, significantly reducing solid waste discharge into the environment and enabling end users to extract value from industrial waste materials.

TMSR Holding Company (TMSR), closed the day's trading session at $2.15, even for the day. The average volume for the last 3 months is 6,898 and the stock's 52-week low/high is $1.84/$10.322.

Recent News


BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage biotechnology company focused on the development of proprietary targeted immunotherapy for advanced breast cancer, has achieved proof of concept and reported promising results from a Phase IIa study of its lead clinical candidate, Bria-IMT.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.0938, even for the day. The average volume for the last 3 months is 15,235 and the stock's 52-week low/high is $0.068/$0.1387.

Recent News


The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) is pleased to announce the closing of the previously announced acquisition of HemPoland. The transaction has received approval from the Toronto Stock Exchange and cements the Company's commitment to building shareholder value through international expansion. Also today, CannabisNewsWire released a report which highlights the company, examining how the Department of Revenue Administration in New Hampshire has revised its estimates of cannabis revenue upwards to $58 million annually if the products are taxed at 15%. These estimates come at a time when a committee is discussing proposals to legalize recreational marijuana next year.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $4.90, up 0.21%, on 722,213 volume with 2,042 trades. The average volume for the last 3 months is 893,786 and the stock's 52-week low/high is $2.784/$7.8938.

Recent News


VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSXV:VIVO, OTCQX: VVCIF) (“VIVO” or the “Company”), through its wholly owned subsidiary ABcann Medicinals Inc., and Loyalist College’s Applied Research Centre for Natural Products and Medical Cannabis (ARC) have entered into an applied research agreement to investigate and develop innovative processes for the extraction and formulation of cannabis oil for commercialization.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $1.09, off by 0.91%, on 374,173 volume with 399 trades. The average volume for the last 3 months is 641,250 and the stock's 52-week low/high is $0.73/$3.29.

Recent News


SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring SinglePoint, Inc. (OTCQB: SING), a client of NNW focused on acquiring companies that will benefit from the injection of growth capital and technology integration. To view the full publication, titled “Growth of Blockchain Provides Financial Services for Underserved Markets,” visit: Also today, SinglePoint was a featured company on this week’s episode of MoneyTV with Donald Baillargeon. To view the full interview, visit To view the full press release, visit:

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.0311, off by 2.51%, on 2,694,767 volume with 147 trades. The average volume for the last 3 months is 4,279,964 and the stock's 52-week low/high is $0.0235/$0.133.

Recent News


Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP), a client of CNW focused on licensing disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. To view the full publication, titled “Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector,” visit:

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.96, off by 4.39%, on 182,158 volume with 338 trades. The average volume for the last 3 months is 211,123 and the stock's 52-week low/high is $0.3219/$2.539.

Recent News


Canopy Rivers Inc. (TSX.V: RIV)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV).

Canopy Rivers (TSXV: RIV), a unique investment and operating platform, has quickly advanced from its roots and recently began trading on the TSX Venture Exchange. The company was originally founded to diversify Canopy Growth Corp.’s (TSX: WEED) (NYSE: CGC) cannabis supply streams. To view the full article, visit:

Canopy Rivers Inc. (TSX.V: RIV) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a premiere retail cannabis distributor that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Canada’s largest private liquor retailer, Solo Liquor, who collectively have more than 50 years of regulated substance retail experience. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy as “Solo Growth Corp.”
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $5.31, off by 6.51%, on 562,746 volume with 1,429 trades. The stock's 52-week low/high is $3.188/$11.82.

Recent News


665 Energy (SSOF)

The QualityStocks Daily Newsletter would like to spotlight 665 Energy (SSOF).

665 Energy, Inc. (OTC: SSOF), a holding company in the oilfield equipment and supply industry with facilities in Oklahoma, Germany and Dubai, specializes in supplying oilfield equipment, drilling rigs and drilling pipe. A recent name change from 66 Oilfield Services is designed to distinguish the corporate structure of the holding company from its three operating companies: Five Star Rig and Supply; Oklahoma Rig Fabricators; and 66 Oilfield Services, according to a recent news release (

Headquartered in Oklahoma City, 665 Energy (SSOF), formerly Sixty Six Oilfield Services, has been a leading industry expert in the drilling equipment sector of the oil and gas industry for nearly six decades. The company’s sales and rental department provides solutions for domestic and international markets with core offerings that include a wide variety of customized drilling rigs and other select equipment.

665 Energy recently completed the acquisition of Fluid End Sales, doing business as Five Star Rig and Supply, which was established as a family owned business in 1984. The company’s focus continues to be on supplying the oil industry with custom drilling rigs, heavy-weight drill pipe, drill collars, pup joints, pony collars, handling tools, tubing, casing, blow-out preventers, engines, compressors and other select equipment to customers worldwide through its facilities in Oklahoma, Germany and Dubai. The company’s services include the sale of new equipment, sale of refurbished and certified used equipment, as well as rental of oilfield equipment.

Immediate expansion plans include partnering with a rig debt financing company to fund the $40 million purchase of 11 identified oil drilling rigs that have already been appraised. This action represents an incredible opportunity to jumpstart the next phase of growth and expansion.

Company president and CEO Jason Clayton, who started at Five Star in 1993, has worked in and managed all areas of the company including customer growth and sales. Clayton will also remain as president of the subsidiary, Five Star Rig and Supply, and is supported by longtime key staff members including Jimmy Joslin, who has been with Five Star Rig since 1984 and will be responsible for orders processing, inventory control, delivery, logistics and supervision of custom projects such as rig and rig equipment refurbishment, testing and certification. Jim Frazier will assume the role of CFO as the company prepares for further growth and expansion.

According to a research report by Statista, the world’s oil and gas equipment industry is projected to be worth nearly USD$205 billion by 2020 (, and as the energy sector continues strong growth in 2018, 665 Energy is well positioned to capitalize on the global trend and will continue to be aggressive in the marketplace.

665 Energy (SSOF), closed the day's trading session at $0.0058, off by 7.94%, on 1,076,842 volume with 15 trades. The average volume for the last 3 months is 3,474,214 and the stock's 52-week low/high is $0.0006/$0.019.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.